Metabolic syndrome, its components, and gastrointestinal cancer risk: a meta‐analysis of 31 prospective cohorts and Mendelian randomization study
Journal of Gastroenterology and Hepatology · 2024-04 · 39 (4) · 630-641
DOI: 10.1111/jgh.16477 ↗Kurz gefasst
Metaanalyse in der Zeitschrift Journal of Gastroenterology and Hepatology, online erschienen am 17.01.2024. Verfasst von Zhi-Qing Zhan und 8 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterology and Hepatology; Shanghai Institute of Digestive Disease; NHC Key Laboratory of Digestive Diseases; State Key Laboratory …. Hauptthemen laut MEDLINE: Gastrointestinal Neoplasms, Mendelian Randomization Analysis, Metabolic Syndrome. Die Arbeit wurde bisher 56-mal zitiert (Crossref) und nennt 22 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Shanghai Jiaotong University "STAR" plan, Shanghai Municipal Education Commission-Gaofeng Clinical Medicine Grant Support.
Abstract (Originalsprache)
Background and Aim Cohort studies have linked metabolic syndrome (MetS) to gastrointestinal (GI) cancer risk. We aimed to evaluate the associations between MetS, its components, and combinations of MetS components with eight GI cancers risk.
Methods
We conducted a systematic search of prospective cohort studies and performed a meta‐analysis. Subgroup analyses regarding diagnostic criteria, sex, cancer sites, histological subtypes, ethnic groups, and studies adjusted for alcohol consumption were carried out. Mendelian randomization (MR) was employed to evaluate the causality between 17 MetS‐related traits and eight GI cancers among Europeans and Asians separately.
Results
Meta‐analyses of 31 prospective studies indicated that MetS was significantly associated with an increased risk of colorectal cancer (CRC) (RR [95% CI] = 1.13 [1.12–1.15]), esophageal cancer (EC) (RR [95% CI] = 1.17 [1.03–1.32]), gallbladder cancer (GBC) (RR [95% CI] = 1.37[1.10–1.71]), liver cancer (LC) (RR [95% CI] = 1.46 [1.29–1.64]), and pancreatic cancer (PaC) (RR [95% CI] = 1.25 [1.20–1.30]), but not gastric cancer (GC) (RR [95% CI] = 1.11 [0.96–1.28]). Regarding the associations between MetS components and GI cancers risk, the following associations showed statistical significance: obesity‐CRC/LC/EC/, hypertriglyceridemia‐LC/PaC, reduced high‐density lipoprotein (HDL)‐CRC/LC/GC/PaC, hyperglycemia‐CRC/LC/PaC, and hypertension‐CRC/LC/EC/PaC. Sex‐specific associations were observed between individual MetS components on GI cancers risk. Among the top three common combinations in both sexes, obesity + HTN + hyperglycemia had the strongest association with CRC risk (RR [95% CI] = 1.54 [1.49–1.61] for males and 1.27 [1.21–1.33] for females). MR analyses revealed causality in 16 exposure–outcome pairs: waist‐to‐hip ratio/BMI/HbA1c‐CRC; BMI/childhood obesity/waist circumference/T2DM/glucose‐EC; BMI/waist circumference/cholesterol‐LC; cholesterol/childhood obesity/waist circumference/HbA1c‐PaC; and HbA1c‐GBC. These results were robust against sensitivity analyses.
Conclusions
Since MetS is reversible, lifestyle changes or medical interventions targeting MetS patients might be potential prevention strategies for GI cancers.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Gastroenterology and Hepatology; Shanghai Institute of Digestive Disease; NHC Key Laboratory of Digestive Diseases; State Key Laboratory for Oncogenes and Related Genes; Renji Hospital, School of Medicine, S…
- Department of Gastroenterology and Hepatology, West China Hospital, Sichuan University, China.
- Department of Clinical Medicine, Guangzhou Medical University, Guangzhou, China.
ORCID-Profile: Zhi-Qing Zhan, Ying-Xuan Chen, Jing-Yuan Fang
Förderung
- National Natural Science Foundation of China
- Shanghai Jiaotong University "STAR" plan
- Shanghai Municipal Education Commission-Gaofeng Clinical Medicine Grant Support
Zitieren
APA
Zhan, Z. Q., Chen, Y. Z., Huang, Z. M., Luo, Y. H., Zeng, J. J., Wang, Y., Tan, J., Chen, Y. X., & Fang, J. Y. (2024). Metabolic syndrome, its components, and gastrointestinal cancer risk: a meta‐analysis of 31 prospective cohorts and Mendelian randomization study. Journal of Gastroenterology and Hepatology, 39(4), 630-641. https://doi.org/10.1111/jgh.16477
Vancouver
Zhan ZQ, Chen YZ, Huang ZM, Luo YH, Zeng JJ, Wang Y, et al. Metabolic syndrome, its components, and gastrointestinal cancer risk: a meta‐analysis of 31 prospective cohorts and Mendelian randomization study. Journal of Gastroenterology and Hepatology. 2024;39(4):630-641. doi:10.1111/jgh.16477
BibTeX
@article{Zhan2024,
author = {Zhan, Zhi-Qing and Chen, Ying-Zhou and Huang, Ze-Min and Luo, Yu-Hua and Zeng, Jia-Jian and Wang, Ye and Tan, Juan and Chen, Ying-Xuan and Fang, Jing-Yuan},
title = {Metabolic syndrome, its components, and gastrointestinal cancer risk: a meta‐analysis of 31 prospective cohorts and Mendelian randomization study},
journal = {Journal of Gastroenterology and Hepatology},
year = {2024},
volume = {39},
number = {4},
pages = {630--641},
doi = {10.1111/jgh.16477}
}
EUVIMED